Stock comparison
Glaukos
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GKOS
Glaukos
Market cap
$7.06B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GKOS | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 70B | HAE |
| Benjamin Graham | 56D | 85A | HAE |
| Philip Fisher | 44D | 60C | HAE |
| Peter Lynch | 29F | 54C | HAE |
| Joel Greenblatt | 2F | 31F | HAE |
| Charlie Munger | 30F | 54D | HAE |
| Terry Smith | 30F | 55D | HAE |
Side-by-side metrics
| Metric | GKOS | HAE |
|---|---|---|
| Market cap | $7.06B | $2.98B |
| P/E (TTM) | - | 24.8x |
| EV/EBIT | - | 14.1x |
| ROIC (TTM) | -10.4% | 8.37% |
| Gross margin | 78.08% | 55.74% |
| Net margin | -34.34% | 7.29% |
| Revenue CAGR 5y | 14.62% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 0.2x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GKOS leads on
- P/E (TTM)-vs 24.8x+156%
- EV/EBIT-vs 14.1x+114%
- Debt / Equity0.2xvs 1.5x+90%
- Market cap$7.06Bvs $2.98B+58%
HAE leads on
- ROIC (TTM)8.37%vs -10.4%+181%
- Net margin7.29%vs -34.34%+121%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.